Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories The partnership brings together…
Samsung Bioepis and Teva Pharmaceutical Industries have entered into a strategic partnership to develop and commercialize up to six potential biosimilar candidates. Two biosimilar candidates, SB41 and SB44, have been confirmed. SB41 references Fasenra (benralizumab) and SB44 references Ilaris (canakinumab). Samsung Bioepis will handle the development, regulatory registration, and manufacturing of the biosimilars, while Teva is responsible for commercialization in global markets, including the U.S., Europe, and Canada.
The agreement includes an option to expand the partnership to other territories. This collaboration strengthens the long-standing partnership between the two companies, which has already led to commercialization successes in the U.S. and Canada. Kyung-Ah Kim, President and CEO of Samsung Bioepis, expressed excitement about the expanded partnership and the potential to improve patient access to life-changing medicines.
Richard Francis, President and CEO of Teva, emphasized the importance of biosimilars in their Pivot to Growth strategy and their ambition to become a leading biopharmaceutical company.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
